Virpax Pharmaceuticals (VRPX) Receives FDA Response and Guidance on MMS019

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Virpax Pharmaceuticals (VRPX) Receives FDA Response and Guidance on MMS019

Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019

August 17, 2021 9:00 AM EDT

--  Company to Pursue Prophylactic Treatment Against SARS and Influenza for Daily Use as an OTC Product --

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax® Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has received a written pre-investigational new drug (pre-IND) response from the U.S. Food and Drug Administration (FDA) for MMS019, its patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product. Virpax... More